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Paclitaxel-Coated Stent:
Is There a Light at the End of the Tunnel?
We read with great interest the study by Drachman et al.(1). Their
study determines long-term effects of stent-based paclitaxel deliv-
ery and its influence on neointimal thickening in a rabbit injury
model.
Their report highlights the importance of stents with drug
delivery capabilities and therefore signals the beginning of the era
of “smart” stents. An important question unanswered in their study
is the gender bias in paclitaxel therapy. It is well established that
the chemotherapeutic effect of paclitaxel is mediated through the
plasma membrane estrogen receptors (2). It is also widely accepted
that this is particularly effective in breast and ovarian neoplasms
(3–5).
In contrast, the estrogen receptors in the human cells, including
arterial smooth muscle cells (SMC), are probably less developed in
the male cell system. Therefore, it will be extremely interesting to
investigate the effect of paclitaxel-coated stents on myointimal
hyperplasia in male and female animals.
Another issue of this antiproliferative approach for restenosis is
the nonselective nature of this modality, which also includes
suppression of endothelial cell growth. Although the Drachman et
al. (1) study along with others demonstrates complete endotheli-
alization of the coated stents at follow-up, histology is not always
an absolute indicator of the endothelialization process. Many
believe there is the phenomenon of pseudo-endothelialization.
Synthetic or proliferative SMC that line the surface of the vessel
after injury may perform many, but not all, functions of endothelial
cells. Therefore, functional studies are necessary to address the
issue of true endothelialization and, subsequently, late thrombosis.
Finally, the issue of modulation of collagen production by SMC
needs to be addressed. The arrest of SMC migration and prolif-
eration will not be enough to reverse the process of restenosis. It
might be that paclitaxel therapy of the vessel wall also abolishes
collagen production. Importantly, further in vitro and in vivo
studies will help to understand antirestenotic properties of this
compound.
Thus, additional experimental studies that will address all these
issues might indeed allow us to see the beginning of the end of a
long and difficult journey of restenosis prevention.
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REPLY
We very much appreciate the comments of Kipshidze et al.
regarding our report on long-term reduction of experimental
restenosis using a paclitaxel-releasing stent (1). Their insights
underscore the challenges we all face in translating “bench-top”
triumphs to techniques that benefit our patients.
It is interesting to consider the role played by the estrogen
receptor in smooth muscle cell migration and proliferation (2), and
it will be important to determine whether paclitaxel’s antirestenotic
effects are, at least in part, effected through this receptor system. It
is worth noting, however, that paclitaxel’s effects are myriad, and
that attributing all to plasma membrane estrogen receptors may
not be accurate. Such mechanistic insight may extend our under-
standing of clinical restenosis.
We reiterate concerns that experimental models of endothelial
cell function are incomplete and may not always mirror responses
in humans. Following experimental arterial injury, the endothe-
lium plays an important role in guiding the healing process,
modulating neointimal proliferation, controlling extracellular ma-
trix deposition, regulating vasomotor tone, and protecting against
luminal thrombus deposition. Although present laboratory meth-
ods allow us to examine the histologic impact of arterial injury on
endothelial viability, specific aspects of endothelial cell function are
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more difficult to characterize. In particular, the scaffolding effect of
an endoluminal stent renders impossible examination of the
influence of endothelial function on vasomotor tone. Nevertheless,
our results demonstrating von Willebrand factor (vWf) immuno-
reactivity indicate complete anatomic endothelialization of nonde-
nuded arteries at three days and significant reendothelialization in
denuded vessels 180 days following paclitaxel-releasing stent im-
plantation. Smooth muscle cells on the surface would not possess
vWf immunoreactivity.
In our study, the presence of collagen was markedly reduced by
paclitaxel up to six months following stent implantation. The
persistence of fibrin and inflammatory cells and relative absence of
collagen or smooth muscle cells in the neointima indicate near-
total arrest of the healing process. By examining the impact of
paclitaxel on collagen deposition and other wound-healing param-
eters, we may gain critical insights into the determinants of clinical
restensosis and potential therapeutic techniques.
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